Lun Li1, Dongdong Han2, Xiaowei Wang3, Quan Wang4, Jinhui Tian5, Jia Yao1, Liqin Yuan1, Ke Qian1, Qiongyan Zou1, Wenjun Yi1, Enxiang Zhou1, Kehu Yang5. 1. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. 2. Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China. 3. Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China. 4. Department of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, Xijing Hospital, Four Military Medical University, Xi'an, Shaanxi, China. 5. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Abstract
AIM: To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients. METHODS: PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis. RESULTS: 49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before: hazard ratio [HR]: 2.29; 95% CI: 1.42-3.69; after: HR: 2.24; 95% CI: 1.82-2.75) and disease-free survival (DFS; before: HR: 1.54; 95% CI: 1.23-1.95; after: HR: 2.08; 95% CI: 1.83-2.37). Low/no reduction or increase might be associated with worse DFS (HR: 2.13; 95% CI: 1.51-3.02) and OS. CONCLUSION: Ki-67 before and after neoadjuvant chemotherapy, as well as the change could predict the prognosis for breast cancer patients.
AIM: To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancerpatients. METHODS: PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis. RESULTS: 49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before: hazard ratio [HR]: 2.29; 95% CI: 1.42-3.69; after: HR: 2.24; 95% CI: 1.82-2.75) and disease-free survival (DFS; before: HR: 1.54; 95% CI: 1.23-1.95; after: HR: 2.08; 95% CI: 1.83-2.37). Low/no reduction or increase might be associated with worse DFS (HR: 2.13; 95% CI: 1.51-3.02) and OS. CONCLUSION:Ki-67 before and after neoadjuvant chemotherapy, as well as the change could predict the prognosis for breast cancerpatients.
Authors: Alexey Surov; Paola Clauser; Yun-Woo Chang; Lihua Li; Laura Martincich; Savannah C Partridge; Jin You Kim; Hans Jonas Meyer; Andreas Wienke Journal: Breast Cancer Res Date: 2018-06-19 Impact factor: 6.466